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Background—Ovarian cancer is a leading cause of cancer-related death among women. In an
effort to understand contributors to disease outcome, we evaluated single-nucleotide
polymorphisms (SNPs) previously associated with ovarian cancer recurrence or survival,
specifically in angiogenesis, inflammation, mitosis, and drug disposition genes.
Methods—Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and
ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive
cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000
observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine
the association between candidate SNPs and ovarian cancer recurrence or survival with and
without adjustment for key covariates.
Results—We observed no association between genotype and ovarian cancer recurrence or
survival for any of the SNPs examined.
Conclusions—These results refute prior associations between these SNPs and ovarian cancer
outcome and underscore the importance of maximally powered genetic association studies.
Impact—These variants should not be used in prognostic models. Alternate approaches to
uncovering inherited prognostic factors, if they exist, are needed.
INTRODUCTION
In 2012, ovarian cancer was estimated to be the seventh leading cause of female cancer-
related deaths worldwide (1). Despite standardized treatment approaches, inter-individual
variation in outcomes exists; understanding the source of this variation, including potential
inherited factors, is of high importance (2). Our prior studies of over 400 candidate genes in
biological pathways that are relevant to ovarian cancer suggested association between
ovarian cancer outcome and inherited variation in certain genes (3–5). These include the
angiogenesis genes VHL (3) and HGF (4), taxol efflux and metabolism genes ABCB1 and
CYP2C8 (5), DNA repair genes ERCC2 and ERCC1 (5), the inflammation gene IL18 (3),
and the mitosis gene PRKACB (4). Here, we sought to confirm prior associations (p<0.05)
between ovarian cancer outcome and 27 single-nucleotide polymorphisms (SNPs) in these
genes using a much larger sample size than the discovery studies.
MATERIALS AND METHODS
A total of 10,084 women with invasive epithelial ovarian cancer (over 37,000 person-years
follow-up) including 5,248 high-grade serous cases were examined. Participants from 28
studies (Table 1) in the Ovarian Cancer Association Consortium (OCAC) were genotyped
on a custom Illumina iSelect BeadArray using centralized genotype calling and quality
control procedures, as previously described (6). In brief, we excluded SNPs and samples
with call rate < 95%; we restricted to women with > 90% predicted European ancestry and
estimated principal components (PCs) representing European substructure (6).
Cox proportional hazards regression modeling accounting for left truncation and censoring
at 10 years following diagnosis was used to estimate per-allele hazard ratios (HRs) and 95%
confidence intervals (CIs) for associations with death from any cause for all cases and for
high-grade serous cases. Two models were assessed: a minimally adjusted model including
covariates for age at diagnosis, five population substructure PCs, and study site, and a fully
adjusted model which additionally included histology (for analyses of all cases only), tumor
stage, tumor grade, and oral contraceptive use as these covariates were associated with
survival in these data (p<0.05). Analyses were also conducted with a recurrence endpoint
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defined by time to disease recurrence or death (377 additional events, including 273 among
women with high-grade serous disease).
RESULTS
Overall, there were no associations between SNPs and ovarian cancer survival in either the
minimally or fully adjusted models; Table 2 shows HRs, 95% CIs, and p-values for all cases
and high-grade serous cases. No heterogeneity across studies was observed (p-values>0.05).
SNP rs2214825 in HGF was significantly associated with survival in the minimally adjusted
model (p=0.03), although not in the fully adjusted model (Table 2). After excluding 2,015
women who contributed to the original report (4), no association was seen at p<0.05
(minimally adjusted HR=1.04, 95% CI=0.98–1.10, p=0.19). Additionally, in ERCC2, SNP
rs50872 conferred a slightly increased risk of death among women with high-grade serous
disease (p=0.03) in the fully adjusted model, but this association was not statistically
significant at α=0.05 in the minimally adjusted model, and, after excluding 497 women in
the original report (5), no statistically significant association was seen (fully adjusted
HR=1.06, 95% CI=1.00–1.14, p=0.06). Near identical results were seen for these SNPs in
analysis of time to recurrence. On the whole, while these candidates showed promise with
large effect sizes (i.e., HRs >1.23 or <0.82) in earlier reports (3–5), our very large scale
study refutes association at these loci with 95% CIs excluding prior risk estimates.
DISCUSSION
Here, we aimed to confirm the relationship between previously-associated SNPs and ovarian
cancer outcome using a sample of over 10,000 women from 28 studies participating in the
OCAC. Results of this analysis did not confirm the associations originally observed (3–5).
While associations with other SNPs may exist, we report no consistent associations between
these 27 SNPs and ovarian cancer outcome and believe it critical to disseminate results to
reduce the possibility of publication bias. These null results highlight the necessity of large-
scale replication of initial SNP associations, as the most likely explanation for non-
replication is that initial false positive findings resulted from chance in smaller studies.
Studies of SNPs and cancer outcome have been less fruitful than cancer susceptibility
studies (7). This may be due to several challenges: lack of a large collection of
homogeneous cases due to missing baseline clinical data, inability to verify
chemotherapeutic or surgical data to evaluate whether SNP effects arise only in certain
clinical contexts, and inconsistent follow-up methods leading to variable completeness of
endpoints (8). Although ovarian cancer has high mortality rate and a generally uniform
treatment compared to other cancers, there is a trade-off in expected power between the
larger sample sizes of observational studies and the detailed data available from clinical
trials. We propose that utilization of both study designs, including detailed tumor
characteristics and coordination with animal and mechanistic studies, is the best path
forward for the identification of predictive and prognostic factors in ovarian cancer
outcomes.
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